Kidney failure is one of the few clinical settings where plasmalogens have been measured in real patients repeatedly, by independent groups, across nearly thirty years. That makes the literature unusually informative, and also unusually easy to over-read. The studies below consistently find lower plasmalogen levels in people with advanced kidney disease, and one found that a low level at the start of dialysis tracked with later cardiovascular death. None of them tested a supplement. This page sets out what was measured, in whom, and what those measurements can and cannot support. Nothing here is medical advice, and nobody with kidney disease should start a supplement on the strength of a biomarker study.
Key Takeaways
- Three separate patient cohorts, published in 1998, 2002 and 2004, all found reduced plasmalogen levels in advanced chronic kidney failure compared with healthy controls.
- In haemodialysis patients, mean serum 16:0 DMA was 0.53 versus 0.67 in controls (p < 0.001), but that gap disappeared once the control group was restricted to people over 85, which is a real limit on how the result should be read.
- In 105 patients followed from the start of renal replacement therapy, those who later died of cardiovascular causes had a lower baseline plasmalogen ratio than those who survived: relative risk 1.50, 95% confidence interval 1.07 to 2.16, independent of age, sex, diabetes and existing cardiovascular disease.
- All three studies used plasmalogens as a surrogate marker of oxidative stress, not as a nutrient under test. The finding is that the marker runs low, not that raising it helps.
- No published trial has given a plasmalogen supplement to people with chronic kidney disease. Reduced clearance also changes how supplements behave, so this is a question for a nephrologist rather than one to settle from research summaries.
Why Kidney Researchers Started Measuring Plasmalogens at All
The interest did not begin with brain health. It began with a long-standing puzzle: people with advanced kidney failure develop cardiovascular disease far earlier and far more often than their conventional risk factors predict, and free-radical damage has long been proposed as part of the explanation. Plasmalogens carry a vinyl ether bond that is preferentially consumed by oxidants, so a falling plasmalogen level can be read as a record of oxidative exposure. That is the entire logic behind treating them as a surrogate marker, and it rests on the same chemistry described in our article on the plasmalogen antioxidant mechanism.
A 1998 study measured erythrocyte membrane plasmalogen ratios in 105 patients with advanced chronic renal failure before they began dialysis, alongside 29 healthy controls. Both ratios used, 16:0 DMA relative to C16:0 and 18:0 DMA relative to C18:0, were significantly lower in the patients. The reduction was more pronounced in patients assessed as malnourished, which suggests nutritional status and oxidative burden were not independent of one another in this population[1].
The Haemodialysis Cohort, Including the Caveat That Matters
A 2002 study took a different measurement in a different group: fasting serum phospholipid plasmalogens, by gas chromatography, in 30 patients on repeated ambulatory haemodialysis compared with 99 healthy control subjects. Mean 16:0 DMA was 0.53 in the patients versus 0.67 in controls (p < 0.001), and 18:0 DMA was 0.33 versus 0.40 (p < 0.01)[2].
The part of that paper worth reading twice is what happened when the authors changed the comparison group. The difference between patients and controls vanished once the controls were restricted to subjects older than 85 for 16:0 DMA, or older than 75 for 18:0 DMA. Put plainly, the plasmalogen level of a dialysis patient of average age resembled that of a healthy person several decades older. That is a vivid way to state the finding, but it also means age is doing a great deal of work in the comparison, and any summary that omits it overstates the result. The age-related decline itself is covered separately in our piece on how plasmalogen levels change with age.
The Mortality Signal, and What It Does Not Establish
The 2004 study is the one most often cited, because it is prospective. The same 105 patients had their erythrocyte plasmalogen ratio measured at the start of renal replacement therapy and were then followed for roughly five years. The 38 who died of cardiovascular causes had a mean 16:0 DMA to C16:0 ratio of 0.066, compared with 0.078 in the 15 who died of non-cardiovascular causes and 0.075 in the 52 alive at follow-up. A Cox proportional hazards model gave a relative risk of 1.50 (95% confidence interval 1.07 to 2.16) for a below-median ratio, independent of age, sex, diabetes and pre-existing cardiovascular disease[3].
That confidence interval deserves a direct look. Its lower bound sits at 1.07, barely above the no-effect line, so this is a real but modest association in a single cohort of roughly a hundred people. More importantly it is an association between a marker and an outcome. The study was not designed to show that low plasmalogens cause cardiovascular death, and it cannot separate that from the simpler reading: that sicker patients carrying more oxidative stress have both lower plasmalogens and worse outcomes. The broader relationship between plasmalogens and heart disease is covered in our cardiovascular article.
What This Means If You Have Kidney Disease
It means the biology is genuinely interesting and the clinical instruction set is empty. No published trial has enrolled people with chronic kidney disease to test whether a plasmalogen supplement changes their plasmalogen levels, their oxidative stress markers, or any clinical outcome at all. These three studies measured a marker. They did not attempt to move it, and a marker that reflects disease severity will not necessarily improve anything when raised directly.
There is also a safety consideration specific to this group that has nothing to do with plasmalogens as such. Reduced kidney clearance changes how supplements behave, and many supplement products carry mineral loads that are managed carefully in kidney disease. Anyone with chronic kidney disease, on dialysis or not, should treat a supplement decision as something to raise with their nephrologist. If you are curious about your own levels, the available blood testing options are described separately, though a test result is not a substitute for clinical advice.
Frequently Asked Questions
Are plasmalogen levels low in kidney disease?
Yes, in the cohorts that have been measured. Studies published in 1998, 2002 and 2004 all found lower plasmalogen levels in patients with advanced chronic renal failure or on dialysis than in healthy controls. The 2002 study noted the difference disappeared when controls were restricted to people over 85, so age accounts for part of the comparison.
Does a low plasmalogen level predict cardiovascular death in dialysis patients?
One prospective study of 105 patients found that a below-median plasmalogen ratio at the start of renal replacement therapy was associated with cardiovascular mortality, with a relative risk of 1.50 and a confidence interval of 1.07 to 2.16. That is a modest association in a single cohort, and an association between a marker and an outcome is not evidence that the marker caused it.
Should someone with kidney disease take a plasmalogen supplement?
No trial has tested plasmalogen supplementation in people with chronic kidney disease, so there is no evidence base to draw on. Reduced kidney clearance also changes how supplements behave. This is a decision to raise with a nephrologist, not one to make from biomarker research.
References
- Brosche T, Platt D. A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrology Dialysis Transplantation (1998). PMID 9794566
- Brosche T, Platt D, Knopf B. Decreased concentrations of serum phospholipid plasmalogens indicate oxidative burden of uraemic patients undergoing haemodialysis. Nephron (2002). PMID 11744806
- Stenvinkel P, Diczfalusy U, Lindholm B, Heimburger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrology Dialysis Transplantation (2004). PMID 15031358
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
